People · Operator
Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Redona Therapeutics, Inc. | — | Biotechnology | Series C | $66.8M | $76.2M | 2018 |
| Obsidian Therapeutics, Inc. | — | Biotechnology | Series B | $32.4M | $1.3B | 2017 |
Carolyn Ng at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carolyn Ng on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 1 | 18 |
| Luke Evnin | 1 | 12 |
| Briggs Morrison | 1 | 8 |
| Michal Silverberg | 1 | 7 |
| David Neafus | 1 | 7 |
| Michael Gilman | 1 | 6 |
| JASON GARDNER | 1 | 5 |
| Marian Nakada | 1 | 4 |
| Kazumi Shiosaki | 1 | 4 |
| Karen Hong | 1 | 4 |
| Christine Brennan | 1 | 3 |
| Henrijette Richter | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.